Shots: The approval is based on P-III ADAURA trial assessing Tagrisso (80mg, qd, PO) vs PBO in 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete tumor resection […]readmore
Tags : Early-Stage
Shots: The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround […]readmore
Shots: OncoCyte acquires 25% stake in Razor and has an option to acquire its remaining shares. Razor to receive $10M for initial acquiring of 25% stock in its preferred share […]readmore